AstraZeneca pays $50 million for rights to Merck cancer drug
(Reuters) - Merck & Co Inc has licensed its experimental cancer drug to AstraZeneca Plc for a $50 million upfront fee in a deal that shows Britain's second-biggest drugmaker continuing to rebuild its pipeline.
Under the terms of the agreement, Merck, the No. 2 U.S. drugmaker, will also be eligible to receive future payments related to development and regulatory milestones, as well as tiered royalties.
The drug, MK-1775, is currently in mid-stage trials in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer.
(Reporting by Shailesh Kuber; Editing by Sreejiraj Eluvangal)
- Malaysian plane still missing; questions over false IDs |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Malaysian plane crashed off Vietnam coast: state media